Henry Schein's Stock Ratings

UBS Analyst

Henry Schein is an analyst at UBS. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/29/2025

Overall Average Return

-%

Smart Score

Overall Average Return Percentile

-

Number of Ratings

1

		Buy Now								Get Alert
08/08/2022	HSIC	Buy Now	Henry Schein	$68.62	16.58%	Henry Schein1%	→ $80	Upgrade	Sell → Neutral	Get Alert

Recent Analyst Stock Rating News

CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Breaking Down Henry Schein: 7 Analysts Share Their Views

Henry Schein Q4 Earnings And Outlook Miss Expectations, Restructures For Growth

Henry Schein Q4 sales grew 5.8% to $3.19 billion, missing estimates. The company was restructured into three segments.

Earnings Scheduled For February 25, 2025

Is Henry Schein Gaining or Losing Market Support?

This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

KKR Raises Bid In Fierce Takeover Battle Of Fuji Soft, Bain Weighs Next Steps: Report

Bain Capital may withdraw tender offer for Fuji Soft, after KKR raised bid in intense bidding war. Global investors target Japan for deals.

What Analysts Are Saying About Henry Schein Stock

KKR Sinks Its Teeth Into Henry Schein With Additional Investment And Board Seats: Details

Henry Schein shares up on strategic investment from KKR, management appointments, share buyback, and preliminary results.

Headline Risks Affecting Healthcare Tech & Distribution Sector Will Likely Continue in 2025: BofA Analyst

BofA sees 2025 challenges for healthcare tech and distributors but upgrades Cardinal Health and Henry Schein, highlighting growth and recovery potential.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook